PROGRAM CHAIR
David Cherney, MDCM, PhD, FRCP(C)
Professor of Medicine – University of Toronto
Clinician Scientist – Division of Nephrology, University Health Network
Senior Scientist, Toronto General Hospital Research Institute
Director, Renal Physiology Laboratory, University Health Network
Toronto, Canada
Roberto Pontremoli, MD, PhD
Full Professor, Department of Internal Medicine
Director, Internal Medicine Clinic
Director, School of Emergency and Urgent Medicine
San Martino Hospital of Genoa
Institute of Scientific Hospitalization and Care
Genoa, Italy
PROGRAM OVERVIEW
This dynamic presentation will examine the barriers to the early identification of CKD as well as evaluate both established and emerging therapies for CKD via the implementation of a multidisciplinary approach. Learn more about strategies for the formulation of clinical management, based on clinical guidelines, for a comprehensive approach to CKD management.
TARGET AUDIENCE
This educational activity is intended for global nephrologists.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe barriers to the early identification of CKD and strategies to overcome them
- Evaluate the safety and efficacy of established and emerging therapies for CKD
- Apply clinical guidelines when formulating management strategies for patients with CKD
- Implement multidisciplinary care for patients with CKD
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
EACCME CREDIT DESIGNATION STATEMENT (For EU Learners)
The AMA (American Medical Association) and UEMS (European Union of Medical Specialists) have an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at [email protected].
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| David Cherney, MDCM | Discloses that he has done consulting for Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, and Novartis. He has done contracted research for Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. He has received honoraria from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, AbbVie, Janssen, Bayer, Prometic, BMS, Maze, Gilead, CSL-Behring, Otsuka, Novartis, Youngene, Lexicon, Inversago, GSK, and Novo-Nordisk and has received operational funding for clinical trials from Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca, CSL-Behring, and Novo-Nordisk. |
| Roberto Pontremoli, MD | Discloses that he is on the speaker’s bureau at Boehringer Ingelheim and Lilly. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of the activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Deborah Anderson, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs (eg,. physical, dietary, etc). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 25, 2024
EXPIRATION DATE: September 25, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
